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Myc family proteins promote cancer by inducingwidespread changes
in gene expression. Their rapid turnover by the ubiquitin–protea-
some pathway is regulated through phosphorylation of Myc Box I
and ubiquitination by the E3 ubiquitin ligase SCFFbxW7. However,
N-Myc protein (the product of theMYCN oncogene) is stabilized in
neuroblastoma by the protein kinase Aurora-A in a manner that is
sensitive to certain Aurora-A–selective inhibitors. Here we identify
a direct interaction between the catalytic domain of Aurora-A and
a site flanking Myc Box I that also binds SCFFbxW7. We determined
the crystal structure of the complex between Aurora-A and this
region of N-Myc to 1.72-Å resolution. The structure indicates that
the conformation of Aurora-A induced by compounds such as ali-
sertib and CD532 is not compatible with the binding of N-Myc,
explaining the activity of these compounds in neuroblastoma cells
and providing a rational basis for the design of cancer therapeutics
optimized for destabilization of the complex. We also propose a
model for the stabilization mechanism in which binding to Aurora-A
alters how N-Myc interacts with SCFFbxW7 to disfavor the genera-
tion of Lys48-linked polyubiquitin chains.
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Myc proteins are transcription factors that markedly altergene expression through both activation and repression of
transcription (1, 2). Three Myc protein family members can be
aberrantly expressed in human cancers. Cellular Myc (c-Myc)
was first discovered as the cellular homolog of the viral Myc
(v-Myc) oncoprotein and is frequently deregulated in a wide range
of human cancers (3–5). N-Myc and L-Myc were subsequently
identified as the products of amplified genes MYCN in neuro-
blastoma and MYCL in small cell lung cancer, respectively (6–8).
Inhibition of Myc is a validated therapeutic strategy, but efforts
to develop clinical compounds that target Myc proteins directly
have failed (9).
c-Myc, N-Myc, and L-Myc have regions of sequence homology
that mediate interactions with critical partner proteins such as
Max, WDR5, TRRAP, PAF1C, and the protein kinase Aurora-A
(10). The most C-terminal of these regions forms an essential
DNA-binding domain through formation of a basic helix–loop–
helix leucine zipper domain in complex with Max (9, 11). Other
conserved sequence motifs called “Myc boxes” (MB0–IV) serve
as docking sites for protein–protein interactions (10, 12, 13). The
Myc transactivation domain (TAD) spans the N-terminal con-
served motifs MB0, MBI, and MBII. The TAD of c-Myc is in-
trinsically disordered, as reported by circular dichroism and NMR
spectroscopy, but there are transient secondary structure elements
that in some cases become stable in complex with binding partners
(12, 14, 15).
The stability of Myc proteins is regulated by phosphorylation
within MBI, which targets the protein for ubiquitinylation and
proteolysis. For example, N-Myc is first phosphorylated on Ser62
by Cdk1/cyclin B and is then phosphorylated on Thr58 by Gsk3β
(16). Dephosphorylation of Ser62 by PP2A directs the activity of
the E3 ubiquitin ligase SCFFbxW7 to modify N-Myc with K48-
linked ubiquitin chains (17, 18). In neuroblastoma cells, the Ser/
Thr protein kinase Aurora-A blocks this process, resulting in an
excess of N-Myc protein (19). Aurora-A binds to the N-Myc/
SCFFbxW7 complex and reduces the proportion of K48 linkages
in the polyubiquitin chains. Catalytic activity of Aurora-A is not
required for N-Myc stabilization, and the underlying mechanism
is unclear. Some Aurora-A inhibitors such as MLN8237/alisertib
and CD532 can destabilize N-Myc by disrupting the complex,
whereas other Aurora-A inhibitors have no effect (19, 20). The
current hypothesis is that the destabilizing inhibitors alter the
conformation of Aurora-A in ways that disrupt the complex, but
inhibitors that compete with ATP without causing a conforma-
tional change leave the complex intact (20–22).
We set out to investigate the structural basis of Aurora-A
stabilization of N-Myc and the effect of Aurora-A inhibitors on
the complex. Here we show that the catalytic domain of Aurora-A
interacts directly with N-Myc through binding sites that flank
either side of MBI. We present a crystal structure of the complex
between Aurora-A and a fragment of N-Myc corresponding
to the region immediately C-terminal to MBI which reveals
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Aurora-A in a fully active conformation that is incompatible with
inhibitors of Aurora-A that disrupt the complex. Biochemical
studies show an interaction between SCFFbxW7 and the same re-
gion of N-Myc, and we propose that the way in which Aurora-A
interferes with this interaction changes N-Myc ubiquitination to
promote stability.
Results and Discussion
Structural Basis of the Interaction Between N-Myc and Aurora-A. To
show that Aurora-A and N-Myc interact directly, we carried out
a coprecipitation experiment using a GST–Aurora-A kinase
domain fusion protein incubated with a range of purified frag-
ments from the N-Myc TAD (Fig. S1A). This method identified
residues 28–89 of N-Myc as the minimal Aurora-A–interaction
region (AIR), which spans MB0 through MBI but does not in-
clude MBII or beyond (Fig. 1A). The binding affinity of Aurora-A
for the AIR was quantified as 2.9 ± 0.5 μM by ELISA (Fig. S1B)
and as 1.0 ± 0.3 μM by competition AlphaScreen assay (Fig. 1B).
The presence of a Trp residue toward the C terminus of this
N-Myc fragment was striking, and mutation of Trp88 to Ala
abrogated the interaction in the context of the entire N-Myc
TAD fragment (residues 1–137) in a precipitation experiment
with GST-tagged Aurora-A catalytic domain (residues 122–403);
the TAD of N-Myc did not interact with GST alone. Taken to-
gether, these results indicate that the interaction is specific
(Fig. S1C).
To elucidate the structural basis of the Aurora-A/N-Myc in-
teraction, we crystallized a complex between the Aurora-A ki-
nase domain with surface Cys mutated to enhance stability
(Aurora-AC290A/C393A) and a synthetic N-Myc peptide corre-
sponding to residues 28–89. The crystals yielded diffraction data
to 1.72-Å resolution, and we solved the structure by molecular
replacement using an existing structure of Aurora-AC290A/C393A
(Table S1 and Fig. S1D). Residues 28–60 of N-Myc are not ob-
served in the structure, whereas residues 61–89 are associated
with the cleft between the N- and C-lobes of the Aurora-A ki-
nase domain formed by the αB/αC helices, the activation loop,
and the αG helix (Fig. 1C). N-Myc residues 76–89 form an
α-helix, which packs onto the C-lobe of Aurora-A at a surface
formed by Tyr334, Gln335, and Tyr338 with its N terminus
pointing toward the substrate-binding region. Both ends of the
α-helix are capped by Trp residues (Trp77 and Trp88), whose side
chains pack against the surface of Aurora-A. Key intermolecular
interactions include a salt bridge between Glu73 of N-Myc and
Lys143 from the Gly-rich loop on the N-lobe of Aurora-A, an
additional interaction between Gln335 of Aurora-A and Trp88 of
N-Myc, and the insertion of the Trp77 side chain of N-Myc into
the hydrophobic P+1 pocket in the activation loop region of
Aurora-A (Fig. 1D). A pair of prolines (Pro74 and Pro75) breaks
the α-helix at its N terminus and directs the chain toward the
Aurora-A N-lobe. Residues 69–71 are hydrogen-bonded into a
turn, and residues 61–67 are bound into a groove between the
N-lobe and the surface formed by the activation loop.
The region of N-Myc observed in the crystal structure starts at
the C terminus of MBI and is not conserved in c-Myc (Fig. S2A).
Our initial mapping suggested that this region was insufficient
for binding, so we used a more sensitive assay based on changes
in fluorescence polarization (FP) using synthetic peptides of
N-Myc to confirm that residues 61–89 of N-Myc bind Aurora-A
independently, with a measured Kd of 12 μM (Fig. S2B). N-Myc
peptides with E73K or W77A mutations reduced binding to
Aurora-A, consistent with their observed contributions to the
interface in the crystal structure (Fig. S2B). Similarly, the con-
tributions of Aurora-A Y334 and Q335 to the interaction were
confirmed.
The section of the AIR that was not resolved in the crystal
structure, residues 28–60 of N-Myc, includes the MB0 and MBI
regions and is conserved in c-Myc (Fig. S2A). Having shown that
the C-terminal part of the AIR was able to bind Aurora-A in-
dependently, we looked for other subfragments that might con-
tribute to binding with a sensitive pull-down assay using peptides
spanning the region, under less stringent conditions than the first
set of pull-downs used for mapping the interaction (Fig. S2C). In
addition to residues 61–89, a region corresponding to MB0 was
also capable of independent interaction with Aurora-A. Using
the FP assay, we confirmed that a peptide spanning residues 19–
47 of N-Myc, including MB0, binds independently to Aurora-A
(Fig. S2D). The presence of conserved aromatic residues in this
region is striking (F28, Y29, F35, Y36), and these residues were
shown to contribute to the interaction with Aurora-A (Fig. S2D).
In contrast to the established roles of the regions flanking it,
MBI itself does not appear to contribute to the interaction with
Aurora-A, because a peptide corresponding to residues 44–64
showed no binding in the peptide coprecipitation assay (Fig.
S2C). Consistent with this result, neither the phosphorylation
status of the phosphodegron residues Thr58 and Ser62 nor
mutation of residues 52–56 to Ala affected Aurora-A binding of
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Fig. 1. Crystal structure of the Aurora-A/N-Myc complex. (A) Domain
structure of N-Myc with conserved regions indicated as boxes and the AIR
marked with a red line. (B) Quantification of the binding affinity between
the Aurora-A kinase domain and the N-Myc AIR by competition AlphaScreen
assay. Data represent the mean of three experiments ± SD. (C) Crystal
structure of the Aurora-AC290A/C393A catalytic domain (AurA, green cartoon)
in complex with N-Myc residues 61–89 (N-Myc, red cartoon). (D) Magnified
view of the structure with key residues shown as sticks.
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the N-Myc 28–89 peptide (Fig. S2E). We postulate that the
flanking regions on either side of MBI form specific interactions
with Aurora-A, linked by the MBI region itself, which interacts
in a phosphorylation-dependent manner with FbxW7 but makes
no critical interactions with Aurora-A.
N-Myc Activates Aurora-A and Competes with TPX2, the Targeting
Protein for Xklp2. When bound to N-Myc, Aurora-A is in a fully
active conformation similar to that observed for the Aurora-A/
TPX2 complex (Fig. 2A) (23). The microtubule-associated pro-
tein-targeting protein for Xklp2 (TPX2) binds to Aurora-A
through its first 43 residues: amino acids 7–21 at a site on the
N-lobe and amino acids 30–43 at a site between the two lobes.
The conformation adopted by Aurora-A when bound to TPX2 is
incompatible with the interaction of N-Myc residues 61–67 (Fig.
2B). There is a clear steric clash, because Leu61 of N-Myc binds
to the same pocket on the Aurora-A surface as Trp34/Phe35 of
TPX2. To accommodate the marked increase in size in going
from the single Leu side chain of N-Myc to the two bulky side
chains of TPX2, the side chain of Aurora-A residue His187 ro-
tates out of the pocket in the TPX2-bound conformation. Side
chains on the αC-helix of Aurora-A such as His176 and Arg179
are also observed in different positions, suggesting that the
N-terminal stretch of TPX2 (Tyr8/Tyr10) that binds on one side of
the αC-helix is incompatible with binding of N-Myc to the other
side of the αC-helix. Consistent with this structural analysis, the
first 43 amino acids of TPX2 and the AIR of N-Myc compete for
binding to Aurora-A (Fig. 2C), and they also have comparable
affinities, because Kd values of 2–3 μM were measured for both
proteins in ELISAs using immobilized Aurora-A (Fig. S1B).
Competition with TPX2 was observed for the individual regions of
the AIR both N- and C-terminal to MB1 (Fig. 2C), suggesting that
the binding site for MB0 on Aurora-A also overlaps with that of
TPX2. The AIR of N-Myc, like TPX2, initially activates
unphosphorylated Aurora-A, so there is also functional overlap
between these two Aurora-A–binding proteins (Fig. 2D and Fig.
S3). The crystal structure reported here does not reveal the
mechanism by which N-Myc activates Aurora-A, because resi-
dues 61–89 of N-Myc were not sufficient to activate Aurora-A,
and we used Aurora-A prephosphorylated on Thr288 to form the
complex. However, it is clear that N-Myc, like TPX2, is able to
trigger Aurora-A activation through protein–protein interac-
tions, and the result is a stabilized conformation of Aurora-A in
which the activation loop forms a platform for the binding of
N-Myc residues 61–89 (Fig. 2E). Furthermore, as shown in Fig.
S3, Aurora-A is able to phosphorylate residues within the 28–89
region of N-Myc efficiently in vitro.
The Conformation of Aurora-A Bound to N-Myc Is Incompatible with
Inhibitors That Destabilize the Interaction. Previous studies showed
that ATP-competitive inhibitors of Aurora-A such as MLN8054,
MLN8237, and CD532 disrupt the formation of the Aurora-A/
N-Myc complex, resulting in destabilization of N-Myc in cell mod-
els. Crystal structures of Aurora-A in complex with MLN8054
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Fig. 2. Structural and functional comparison of Aurora-A interactions with N-Myc and TPX2. (A) Superposition of crystal structures of Aurora-A bound to
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investigate competition between TPX2 (residues 1–43) and N-Myc fragments for binding to Aurora-A (residues 122–403), analyzed by SDS/PAGE. The gel
shows proteins coprecipitated with biotinyl–N-Myc peptides (as indicated) immobilized on streptavidin beads following incubation with 12-μM Aurora-A
catalytic domain in the presence or absence of a fivefold molar excess of TPX2 1–43 protein. (D) Kinase assays to measure the activity of the 0.625-μM initially
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or CD532 show distorted conformations of the kinase, notably in
the positions of the activation loop and the Gly-rich loop (20,
21). In contrast, most Aurora-A inhibitors, such as CCT137690,
do not substantially affect the structure of the protein (24). There
is no available crystal structure of MLN8237 bound to Aurora-A,
but the chemical structures of MLN8054 and MLN8237 are
almost identical, and it is likely that MLN8237 induces a simi-
lar conformation in Aurora-A. We compared the structures of
Aurora-A in complex with N-Myc, MLN8054, CD532, and
CCT137690 (Fig. 3A). Aurora-A grips N-Myc through interactions
involving both the N- and C-lobes of the kinase (colored orange in
Fig. 3A). Binding of CCT137690 does not affect the relative ori-
entation of the two kinase lobes. The activation loop of Aurora-A
is disordered in the Aurora-A/CCT137690 structure because it is
neither phosphorylated nor stabilized by a protein such as TPX2
or N-Myc, and there is no obvious mechanism by which
CCT137690 could affect the activation loop. However, when
Aurora-A is bound to MLN8054 or CD532, the surfaces that form
the binding site for residues 61–89 of N-Myc are moved apart
through motions that twist the two kinase lobes relative to one
another and displace the activation loop (Fig. 3B). The rear-
rangement of this binding site provides a possible mechanism by
which compounds such as MLN8054 disrupt the Aurora-A/N-Myc
complex by acting as a wedge that forces the kinase into an in-
active conformation. The key differences between CCT137690
and MLN8054 are that only the latter makes a specific contact
with the displaced activation loop; although both compounds
contact both the hinge and the Gly-rich loop, the wedge effect is a
function of the 3D shape of MLN8054 in contrast to the flatter
scaffold of CCT137690.
Consistent with the structural analysis, MLN8054 but not
CCT137690 disrupted the direct interaction of the catalytic do-
main of Aurora-A with its binding sites within the AIR (Fig. 3C).
Indeed, Aurora-A bound to MLN8054 displayed two- to threefold
reduced affinity for both of the binding sites within the AIR of
N-Myc compared with Aurora-A alone (Fig. S4). Next, we used
proximity ligation assays to quantify complex formation between
endogenous N-Myc and Aurora-A proteins in a neuroblastoma
cell line (Fig. 3 D and E) and observed significantly fewer inter-
actions in cells treated with MLN8054 or MLN8237 than in un-
treated cells, whereas the number of interactions was unaffected
by treatment with CCT137690.
A Model for the Regulation of N-Myc Ubiquitination by Aurora-A. In
this study, we showed that Aurora-A binds N-Myc irrespective of
its phosphorylation state and interacts with regions of N-Myc
that flank MBI. The binding interaction between the Aurora-A
catalytic domain and N-Myc residues 61–89 that we have re-
solved is immediately adjacent to the phospho-degron motif
centered on Thr58. Phosphorylation of this motif is required for
recognition of N-Myc by SCFFbxW7. Thus, binding of Aurora-A
might affect the interaction of N-Myc with SCFFbxW7. Using
purified proteins, we discovered that SCFFbxW7, like Aurora-A,
interacts with N-Myc irrespective of the phosphorylation state of
Thr58/Ser62 (Fig. 4A). Binding of SCFFbxW7 to N-Myc that is
phosphorylated on Thr58/Ser62 was not affected by Aurora-A, as
is consistent with nonoverlapping binding sites on N-Myc. In
contrast, Aurora-A competed with SCFFbxW7 for binding to
unphosphorylated N-Myc. This observation suggested that the
interaction of SCFFbxW7 with unphosphorylated N-Myc might
depend on a binding site that overlaps with one or both of the
Aurora-A binding sites that flank MBI. Binding of SCFFbxW7 was
mapped to residues 61–89 of N-Myc; binding to residues 48–89 of
N-Myc was also observed, but an unphosphorylated MBI peptide
(residues 44–64) did not bind (Fig. 4B). Aurora-A efficiently
competed with SCFFbxW7 for binding to residues 48–89 of N-Myc
in a dose-dependent manner, whereas a control protein bovine
serum albumin (BSA) did not compete (Fig. 4C). Taken together,
these results show that there is competition between Aurora-A
and SCFFbxW7 for binding to residues 61–89 of N-Myc, the region
bound to Aurora-A in the crystal structure.
These observations suggest a working model by which Aurora-A
could stabilize N-Myc by altering its interaction with SCFFbxW7;
we put forward this model as a basis for further investigation
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(Fig. 4D). Recruitment of N-Myc to SCFFbxW7 is driven by the
well-characterized interaction between the phospho-degron and
FbxW7 that is regulated by phosphorylation of Thr58. However,
a second interaction is also formed between N-Myc residues 61–
89 and an unknown site on SCFFbxW7. Aurora-A binds to N-Myc
at sites that flank the phospho-degron, disrupting the interaction
between residues 61–89 of N-Myc and SCFFbxW7 but not the
phospho-degron region; thus a complex of Aurora-A, N-Myc,
and SCFFbxW7 is formed. We postulate that the interaction be-
tween N-Myc residues 61–89 and SCFFbxW7 is important for effi-
cient polyubiquitination of N-Myc and that disruption of this
interaction by Aurora-A reduces the formation of Lys48-linked
chains on N-Myc, as previously reported (19).
The dysregulation of Myc proteins is a feature of several
cancers that are refractory to treatment, and targeting Myc is a
validated therapeutic strategy (9, 25–27). Unfortunately, there
are currently no drug-like molecules that target Myc directly.
Myc family proteins are intrinsically disordered proteins that
dynamically adopt many conformations and therefore lack
“druggable” pockets. This property has frustrated attempts to
develop a drug-like molecule that directly targets the interaction
of Myc with its binding partners. Here we have characterized the
complex with Aurora-A in which N-Myc is trapped in an ordered
conformation. The interaction can be disrupted by targeting the
ATP-binding site of Aurora-A to induce a conformation that is
incompatible with the binding of N-Myc, and early clinical trial
data suggest these compounds may provide patient benefit when
combined with chemotherapy (20, 22, 28). However, this ap-
proach also would target the main function of Aurora-A in the
proper assembly and the function of the mitotic spindle, and it is
too early to know whether the potential benefit of this in tar-
geting dividing cancer cells offsets the accompanying damage to
normal tissue. Alternatively, it may be possible to inhibit the
protein–protein interaction directly by targeting the interface.
The structure of the Aurora-A/N-Myc complex provides a ra-
tional basis for the development of inhibitors that destabilize
N-Myc and molecular coordinates of the interface that will fa-
cilitate structure-guided approaches to target the binding sites
for ATP or N-Myc on Aurora-A.
Materials and Methods
Crystallography. Aurora-A 122–403 containing the mutations C290A and
C393A was expressed and purified as described previously (29) and was gel-
filtrated into 20 mM Tris (pH 7.5), 200 mM NaCl, 5 mM MgCl2, 5 mM
β-mercaptoethanol, and 10% (vol/vol) glycerol. An N-biotinyl peptide cor-
responding to residues 28–89 of N-Myc and carrying a phosphothreonine at
position 58 (Peptide Synthetics) was dissolved to 10 mM in DMSO. A mixture
containing 300-μM Aurora-A, 5 mM adenosine diphosphate, and 500-μM
N-Myc peptide [with a final DMSO concentration of 5% (vol/vol)] was in-
cubated on ice for 1 h and then mixed 1:1 with reservoir solution [100 mM
Bicine (pH 9.0), 20% (wt/vol) PEG 6000]. Crystals were obtained by vapor
diffusion at 18 °C within a few days and were frozen in reservoir solution
supplemented with 25% (vol/vol) ethylene glycol. Diffraction data were
collected from a single crystal at Diamond I03 and processed with xia2 (30)
(Table S1). The structure of the Aurora-A/N-Myc complex was solved by
pT
58
/pS
62
no
 ph
os
.
19
-38
19
-47
28
-47
28
-60
44
-64
48
-89
61
-89
76
-90
be
ad
s
kDa28-89
17
14
6
3
streptavidin
98anti-GST
    WB
Coomassie
GST-FbxW7
kDa
 28-89
N-Myc
28
38
17
14
6
3
 122-403
AurA
streptavidin
pT58/pS62 no phos.input beads
AurA
 SCFFbxW7
+     -
-     +
+     -
-     + 
+
+ 
+     -
-     + 
+
+ 
+     -
-     + 
+
+ 
Coomassie
biotinyl-N-Myc
28-89 peptides
98 GST-FbxW7anti-GST
    WB
A
B
input
kDa
 48-89
N-Myc
28
38
17
14
6
3
 122-403
AurA
streptavidin
49
62
Au
rA
 
SC
F 
Fb
xW
7
 
BS
A
0 3 9 271
AurA ( M)
 
27
 M
 BS
A
 
be
ad
s
anti-GST
    WB
Coomassie
98 GST-FbxW7
biotinyl-N-Myc 48-89C
‘
low
’
Lys48-linked 
poly-Ub
SCF
P
N-Myc
Ub
Ub
Ub
Ub
‘high ’
Lys48-linked 
poly-Ub
Ub
Ub
Ub FbxW7
SCF
Ub
Ub
Ub
AurA
N-Myc
D
P
E2 E2
FbxW7
  N-Myc
 peptides
Fig. 4. Aurora-A alters the interaction of N-Myc with SCFFbxW7. (A, Upper)
Competition coprecipitation experiments using biotinylated N-Myc AIR
peptides immobilized on streptavidin beads and incubated with 2 μg of the
SCF complex incorporating GST-tagged FbxW7 in the presence or absence
of 12-μM untagged Aurora-A catalytic domain. Equal loading of resin was
assessed by Coomassie Blue staining. (Lower) Binding of SCFFbxW7 to N-Myc
was visualized by Western blot (WB) using anti-GST antibody. (B, Upper)
Coprecipitation experiments using biotinylated N-Myc AIR fragment pep-
tides immobilized on streptavidin beads and incubated with 2 μg SCF com-
plex incorporating GST-tagged FbxW7. Equal loading of resin was assessed
by Coomassie Blue staining. (Lower) Binding of SCFFbxW7 to N-Myc peptides
was visualized by Western blot using an anti-GST antibody. Note that in A
and B, despite the uneven appearance of the peptides in the upper panels
because of differences in migration and sensitivity to Coomassie Blue
staining, equal amounts were loaded into the experiments. (C) Coprecipi-
tation experiments showing competition between SCFFbxW7 and Aurora-A
for binding to N-Myc 48–89. Biotinylated N-Myc 48–89 peptide was immo-
bilized on streptavidin beads and incubated with 2 μg of the SCFFbxW7
complex in the presence of Aurora-A at a range of concentrations or with
BSA. FbxW7 coprecipitating with the peptide was visualized by anti-GST
Western blot. (D) A working model to explain how the interaction between
Aurora-A and N-Myc residues 61–89 may reduce ubiquitination to stabilize
N-Myc. In this model, a low-affinity interaction between the 61–89 region
and SCFFbxW7 is required for N-Myc to be modified effectively with K48-
linked polyubiquitin chains, and competitive binding of Aurora-A to this
region interferes with K48-linked polyubiquitination of N-Myc, leading to
reduced proteasomal degradation.
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molecular replacement phasing using Phaser (31) with an existing Aurora-A
structure [Protein Data Bank (PDB) ID code 4CEG] (29) as the search model.
Iterative modeling and refinement were carried out using Coot (32) and
phenix.refine (33). Structure validation was carried out using MolProbity
(34). Crystallographic data, refinement statistics, and details of structure
validation analysis are summarized in Table S1. Structure figures were pre-
pared using PyMOL (www.pymol.org).
Coprecipitation Assay. For in vitro peptide coprecipitation assays, 40 μL of
Strep-Tactin Sepharose beads (IBA) were incubated with 900 μL of 10-μM
N-biotinyl N-Myc peptides for 1 h and then were washed three times with
pull-down buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM MgCl2, 5 mM
β-mercaptoethanol, 0.02% Tween-20]. The beads were then incubated with
900 μL of a solution containing analyte proteins, competing proteins, or
compounds as required for 2 h at 4 °C and were washed three times with
900 μL pull-down buffer. Finally, the beads were eluted by boiling with 80 μL
SDS-loading buffer, and the eluted proteins were analyzed by SDS/PAGE.
Aurora-A 122–403 was used at a final concentration of 12 μM. SCFFbxW7 in-
corporating GST-tagged FbxW7 (Millipore) was used at a final concentration
of 5.5 ng/μL and was visualized in precipitates by Western blotting using an
anti-GST antibody (GE Healthcare).
Competition AlphaScreen Assay. Biotinyl Avi-tagged Aurora-A 122–403 was
produced as described previously (35). Appropriate concentrations of bio-
tinyl Aurora-A 122–403 and 3xFlag-N-Myc 28–89 for use in competition ex-
periments were determined in preliminary cross-titration experiments over a
range of 0–300 nM. The assay buffer was 50 mM Tris (pH 7.5), 150 mM NaCl,
5 mMMgCl2, 5 mM β-mercaptoethanol, 0.02% Tween-20, and 0.1% BSA. For
competition assays, 10 nM biotinyl Aurora-A 122–403, 0.3 nM 3xFlag-N-Myc
28–89, and 0–160-μMAurora-A 122–403 were mixed together and incubated
at RT for 1 h in white, opaque 96-well half-area plates. Streptavidin donor
beads (20 μg/mL) and anti-Flag acceptor beads (PerkinElmer) were added
simultaneously to each reaction under subdued lighting conditions, and the
plate was incubated for a further 90 min. The signal from each reaction was
read using an EnVision multilabel plate-reader (PerkinElmer). Data points
represent the mean of three experiments; error bars indicate SD. Data were
analyzed using GraphPad Prism 6, and the dependence of the AlphaScreen
signal on the concentration of competing Aurora-A 122–403 was fitted by
nonlinear regression to a one-site logIC50 equation in which, under the se-
lected reaction conditions, the IC50 value approximates the Kd. Results are
reported as Kd ± SE.
In Situ Proximity Ligation Assay. Kelly cells were cultured in RPMI 1640 sup-
plemented with heat-inactivated FBS. Compounds (as indicated) at 500 nM
were added 4 h before fixation. Cells were fixed with 4% (vol/vol) para-
formaldehyde for 30 min and permeabilized with PBS containing 0.2% Triton
X-100 for a further 30 min. Cells were incubated with Duolink In situ blocking
solution (Olink Bioscience) for 1 h and then with antibodies against Aurora-A
(GeneTex) and N-Myc (Calbiochem) diluted into the same buffer for an ad-
ditional hour. In situ proximity ligation assays were carried out using the
Duolink kit (Olink Bioscience) according to the manufacturer’s instructions.
Images were collected and analyzed using a Humphrey 730 field analyzer
system (Zeiss). The average number of interactions detected per cell was
calculated, and results are reported as the mean of three independent ex-
periments ± SD.
Kinase Assay. [32P]ATP kinase assays were performed as described (36) with
modifications as follows. Measurement of Aurora-A activity was carried out
using reactions containing 0.625-μM unphosphorylated Aurora-A catalytic
domain, 40-μM myelin basic protein (Sigma), and 0–50-μM N-Myc 28–89,
N-Myc 61–89, or TPX2 1–43 peptides. Reactions were incubated at 21 °C for
45 min, and total incorporation of 32P radioisotope into Aurora-A, N-Myc
28–89, and myelin basic protein was then measured by scintillation counting.
Results are reported as the mean of two independent experiments ± SE.
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